抗統合失調症薬のグローバル市場展望 2023年-2029年:錠剤、カプセル、その他

■ 英語タイトル:Anti-schizophrenic Drugs Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート(データ管理コード:MMG23JU5691)■ 発行会社/調査会社:Market Monitor Global
■ 商品コード:MMG23JU5691
■ 発行日:2023年6月
■ 調査対象地域:グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野:医薬品&医療
■ ページ数:109
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール(受注後2-3営業日)
■ 販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,250 ⇒換算¥494,000見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD4,225 ⇒換算¥642,200見積依頼/購入/質問フォーム
Enterprise User(閲覧人数制限なし)USD4,875 ⇒換算¥741,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[抗統合失調症薬のグローバル市場展望 2023年-2029年:錠剤、カプセル、その他]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

当調査レポートは次の情報を含め、世界の抗統合失調症薬市場規模と予測を収録しています。・世界の抗統合失調症薬市場:売上、2018年-2023年、2024年-2029年
・世界の抗統合失調症薬市場:販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の抗統合失調症薬市場は2022年に000Mドルと評価され、予測期間中に000%のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「錠剤」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

抗統合失調症薬のグローバル主要企業は、Pfizer、 Johnson & Johnson、 AstraZeneca、 Eli Lilly、 Otsuka Pharmaceutical、 Intra-Cellular Therapies、 Sunovion Pharmaceuticals、 Gedeon Richter、 Alkermes、 Indivior、 Alexza Pharmaceuticals、 Noven Pharmaceuticals、 Hisamitsu Pharmaceutical、 Zhejiang Huahai、 Chengdu Kanghong Pharmaceuticalなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL(MMG)は、抗統合失調症薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の抗統合失調症薬市場:タイプ別、2018年-2023年、2024年-2029年
世界の抗統合失調症薬市場:タイプ別市場シェア、2022年
・錠剤、カプセル、その他

世界の抗統合失調症薬市場:用途別、2018年-2023年、2024年-2029年
世界の抗統合失調症薬市場:用途別市場シェア、2022年
・病院、診療所、その他

世界の抗統合失調症薬市場:地域・国別、2018年-2023年、2024年-2029年
世界の抗統合失調症薬市場:地域別市場シェア、2022年
・北米:アメリカ、カナダ、メキシコ
・ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
・アジア:中国、日本、韓国、東南アジア、インド
・南米:ブラジル、アルゼンチン
・中東・アフリカ:トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における抗統合失調症薬のグローバル売上、2018年-2023年
・主要企業における抗統合失調症薬のグローバル売上シェア、2022年
・主要企業における抗統合失調症薬のグローバル販売量、2018年-2023年
・主要企業における抗統合失調症薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Pfizer、 Johnson & Johnson、 AstraZeneca、 Eli Lilly、 Otsuka Pharmaceutical、 Intra-Cellular Therapies、 Sunovion Pharmaceuticals、 Gedeon Richter、 Alkermes、 Indivior、 Alexza Pharmaceuticals、 Noven Pharmaceuticals、 Hisamitsu Pharmaceutical、 Zhejiang Huahai、 Chengdu Kanghong Pharmaceutical

*************************************************************

・調査・分析レポートの概要
抗統合失調症薬市場の定義
市場セグメント
世界の抗統合失調症薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の抗統合失調症薬市場規模
世界の抗統合失調症薬市場規模:2022年 VS 2029年
世界の抗統合失調症薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの抗統合失調症薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の抗統合失調症薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分:錠剤、カプセル、その他
抗統合失調症薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分:病院、診療所、その他
抗統合失調症薬の用途別グローバル売上・予測

・地域別市場分析
地域別抗統合失調症薬市場規模 2022年と2029年
地域別抗統合失調症薬売上・予測
北米市場:アメリカ、カナダ、メキシコ
ヨーロッパ市場:ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場:中国、日本、韓国、東南アジア、インド
南米市場:ブラジル、アルゼンチン
中東・アフリカ市場:トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル(企業概要、事業概要、主要製品、売上、ニュースなど)
Pfizer、 Johnson & Johnson、 AstraZeneca、 Eli Lilly、 Otsuka Pharmaceutical、 Intra-Cellular Therapies、 Sunovion Pharmaceuticals、 Gedeon Richter、 Alkermes、 Indivior、 Alexza Pharmaceuticals、 Noven Pharmaceuticals、 Hisamitsu Pharmaceutical、 Zhejiang Huahai、 Chengdu Kanghong Pharmaceutical
...

This report aims to provide a comprehensive presentation of the global market for Anti-schizophrenic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-schizophrenic Drugs. This report contains market size and forecasts of Anti-schizophrenic Drugs in global, including the following market information:
Global Anti-schizophrenic Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Anti-schizophrenic Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Tablets Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Anti-schizophrenic Drugs include Pfizer, Johnson & Johnson, AstraZeneca, Eli Lilly, Otsuka Pharmaceutical, Intra-Cellular Therapies, Sunovion Pharmaceuticals, Gedeon Richter and Alkermes, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Anti-schizophrenic Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Anti-schizophrenic Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Anti-schizophrenic Drugs Market Segment Percentages, by Type, 2022 (%)
Tablets
Capsules
Other
Global Anti-schizophrenic Drugs Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Anti-schizophrenic Drugs Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Other
Global Anti-schizophrenic Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Anti-schizophrenic Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Anti-schizophrenic Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Anti-schizophrenic Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Johnson & Johnson
AstraZeneca
Eli Lilly
Otsuka Pharmaceutical
Intra-Cellular Therapies
Sunovion Pharmaceuticals
Gedeon Richter
Alkermes
Indivior
Alexza Pharmaceuticals
Noven Pharmaceuticals
Hisamitsu Pharmaceutical
Zhejiang Huahai
Chengdu Kanghong Pharmaceutical
Outline of Major Chapters:
Chapter 1: Introduces the definition of Anti-schizophrenic Drugs, market overview.
Chapter 2: Global Anti-schizophrenic Drugs market size in revenue.
Chapter 3: Detailed analysis of Anti-schizophrenic Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Anti-schizophrenic Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

世界の市場調査レポート販売サイト(H&Iグローバルリサーチ株式会社運営)
*** レポート目次(コンテンツ)***

1 Introduction to Research & Analysis Reports
1.1 Anti-schizophrenic Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Anti-schizophrenic Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Anti-schizophrenic Drugs Overall Market Size
2.1 Global Anti-schizophrenic Drugs Market Size: 2022 VS 2029
2.2 Global Anti-schizophrenic Drugs Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Anti-schizophrenic Drugs Players in Global Market
3.2 Top Global Anti-schizophrenic Drugs Companies Ranked by Revenue
3.3 Global Anti-schizophrenic Drugs Revenue by Companies
3.4 Top 3 and Top 5 Anti-schizophrenic Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Anti-schizophrenic Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Anti-schizophrenic Drugs Players in Global Market
3.6.1 List of Global Tier 1 Anti-schizophrenic Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Anti-schizophrenic Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Anti-schizophrenic Drugs Market Size Markets, 2022 & 2029
4.1.2 Tablets
4.1.3 Capsules
4.1.4 Other
4.2 By Type – Global Anti-schizophrenic Drugs Revenue & Forecasts
4.2.1 By Type – Global Anti-schizophrenic Drugs Revenue, 2018-2023
4.2.2 By Type – Global Anti-schizophrenic Drugs Revenue, 2024-2029
4.2.3 By Type – Global Anti-schizophrenic Drugs Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Anti-schizophrenic Drugs Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Other
5.2 By Application – Global Anti-schizophrenic Drugs Revenue & Forecasts
5.2.1 By Application – Global Anti-schizophrenic Drugs Revenue, 2018-2023
5.2.2 By Application – Global Anti-schizophrenic Drugs Revenue, 2024-2029
5.2.3 By Application – Global Anti-schizophrenic Drugs Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Anti-schizophrenic Drugs Market Size, 2022 & 2029
6.2 By Region – Global Anti-schizophrenic Drugs Revenue & Forecasts
6.2.1 By Region – Global Anti-schizophrenic Drugs Revenue, 2018-2023
6.2.2 By Region – Global Anti-schizophrenic Drugs Revenue, 2024-2029
6.2.3 By Region – Global Anti-schizophrenic Drugs Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Anti-schizophrenic Drugs Revenue, 2018-2029
6.3.2 US Anti-schizophrenic Drugs Market Size, 2018-2029
6.3.3 Canada Anti-schizophrenic Drugs Market Size, 2018-2029
6.3.4 Mexico Anti-schizophrenic Drugs Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Anti-schizophrenic Drugs Revenue, 2018-2029
6.4.2 Germany Anti-schizophrenic Drugs Market Size, 2018-2029
6.4.3 France Anti-schizophrenic Drugs Market Size, 2018-2029
6.4.4 U.K. Anti-schizophrenic Drugs Market Size, 2018-2029
6.4.5 Italy Anti-schizophrenic Drugs Market Size, 2018-2029
6.4.6 Russia Anti-schizophrenic Drugs Market Size, 2018-2029
6.4.7 Nordic Countries Anti-schizophrenic Drugs Market Size, 2018-2029
6.4.8 Benelux Anti-schizophrenic Drugs Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Anti-schizophrenic Drugs Revenue, 2018-2029
6.5.2 China Anti-schizophrenic Drugs Market Size, 2018-2029
6.5.3 Japan Anti-schizophrenic Drugs Market Size, 2018-2029
6.5.4 South Korea Anti-schizophrenic Drugs Market Size, 2018-2029
6.5.5 Southeast Asia Anti-schizophrenic Drugs Market Size, 2018-2029
6.5.6 India Anti-schizophrenic Drugs Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Anti-schizophrenic Drugs Revenue, 2018-2029
6.6.2 Brazil Anti-schizophrenic Drugs Market Size, 2018-2029
6.6.3 Argentina Anti-schizophrenic Drugs Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Anti-schizophrenic Drugs Revenue, 2018-2029
6.7.2 Turkey Anti-schizophrenic Drugs Market Size, 2018-2029
6.7.3 Israel Anti-schizophrenic Drugs Market Size, 2018-2029
6.7.4 Saudi Arabia Anti-schizophrenic Drugs Market Size, 2018-2029
6.7.5 UAE Anti-schizophrenic Drugs Market Size, 2018-2029
7 Anti-schizophrenic Drugs Companies Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Anti-schizophrenic Drugs Major Product Offerings
7.1.4 Pfizer Anti-schizophrenic Drugs Revenue in Global Market (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Company Summary
7.2.2 Johnson & Johnson Business Overview
7.2.3 Johnson & Johnson Anti-schizophrenic Drugs Major Product Offerings
7.2.4 Johnson & Johnson Anti-schizophrenic Drugs Revenue in Global Market (2018-2023)
7.2.5 Johnson & Johnson Key News & Latest Developments
7.3 AstraZeneca
7.3.1 AstraZeneca Company Summary
7.3.2 AstraZeneca Business Overview
7.3.3 AstraZeneca Anti-schizophrenic Drugs Major Product Offerings
7.3.4 AstraZeneca Anti-schizophrenic Drugs Revenue in Global Market (2018-2023)
7.3.5 AstraZeneca Key News & Latest Developments
7.4 Eli Lilly
7.4.1 Eli Lilly Company Summary
7.4.2 Eli Lilly Business Overview
7.4.3 Eli Lilly Anti-schizophrenic Drugs Major Product Offerings
7.4.4 Eli Lilly Anti-schizophrenic Drugs Revenue in Global Market (2018-2023)
7.4.5 Eli Lilly Key News & Latest Developments
7.5 Otsuka Pharmaceutical
7.5.1 Otsuka Pharmaceutical Company Summary
7.5.2 Otsuka Pharmaceutical Business Overview
7.5.3 Otsuka Pharmaceutical Anti-schizophrenic Drugs Major Product Offerings
7.5.4 Otsuka Pharmaceutical Anti-schizophrenic Drugs Revenue in Global Market (2018-2023)
7.5.5 Otsuka Pharmaceutical Key News & Latest Developments
7.6 Intra-Cellular Therapies
7.6.1 Intra-Cellular Therapies Company Summary
7.6.2 Intra-Cellular Therapies Business Overview
7.6.3 Intra-Cellular Therapies Anti-schizophrenic Drugs Major Product Offerings
7.6.4 Intra-Cellular Therapies Anti-schizophrenic Drugs Revenue in Global Market (2018-2023)
7.6.5 Intra-Cellular Therapies Key News & Latest Developments
7.7 Sunovion Pharmaceuticals
7.7.1 Sunovion Pharmaceuticals Company Summary
7.7.2 Sunovion Pharmaceuticals Business Overview
7.7.3 Sunovion Pharmaceuticals Anti-schizophrenic Drugs Major Product Offerings
7.7.4 Sunovion Pharmaceuticals Anti-schizophrenic Drugs Revenue in Global Market (2018-2023)
7.7.5 Sunovion Pharmaceuticals Key News & Latest Developments
7.8 Gedeon Richter
7.8.1 Gedeon Richter Company Summary
7.8.2 Gedeon Richter Business Overview
7.8.3 Gedeon Richter Anti-schizophrenic Drugs Major Product Offerings
7.8.4 Gedeon Richter Anti-schizophrenic Drugs Revenue in Global Market (2018-2023)
7.8.5 Gedeon Richter Key News & Latest Developments
7.9 Alkermes
7.9.1 Alkermes Company Summary
7.9.2 Alkermes Business Overview
7.9.3 Alkermes Anti-schizophrenic Drugs Major Product Offerings
7.9.4 Alkermes Anti-schizophrenic Drugs Revenue in Global Market (2018-2023)
7.9.5 Alkermes Key News & Latest Developments
7.10 Indivior
7.10.1 Indivior Company Summary
7.10.2 Indivior Business Overview
7.10.3 Indivior Anti-schizophrenic Drugs Major Product Offerings
7.10.4 Indivior Anti-schizophrenic Drugs Revenue in Global Market (2018-2023)
7.10.5 Indivior Key News & Latest Developments
7.11 Alexza Pharmaceuticals
7.11.1 Alexza Pharmaceuticals Company Summary
7.11.2 Alexza Pharmaceuticals Business Overview
7.11.3 Alexza Pharmaceuticals Anti-schizophrenic Drugs Major Product Offerings
7.11.4 Alexza Pharmaceuticals Anti-schizophrenic Drugs Revenue in Global Market (2018-2023)
7.11.5 Alexza Pharmaceuticals Key News & Latest Developments
7.12 Noven Pharmaceuticals
7.12.1 Noven Pharmaceuticals Company Summary
7.12.2 Noven Pharmaceuticals Business Overview
7.12.3 Noven Pharmaceuticals Anti-schizophrenic Drugs Major Product Offerings
7.12.4 Noven Pharmaceuticals Anti-schizophrenic Drugs Revenue in Global Market (2018-2023)
7.12.5 Noven Pharmaceuticals Key News & Latest Developments
7.13 Hisamitsu Pharmaceutical
7.13.1 Hisamitsu Pharmaceutical Company Summary
7.13.2 Hisamitsu Pharmaceutical Business Overview
7.13.3 Hisamitsu Pharmaceutical Anti-schizophrenic Drugs Major Product Offerings
7.13.4 Hisamitsu Pharmaceutical Anti-schizophrenic Drugs Revenue in Global Market (2018-2023)
7.13.5 Hisamitsu Pharmaceutical Key News & Latest Developments
7.14 Zhejiang Huahai
7.14.1 Zhejiang Huahai Company Summary
7.14.2 Zhejiang Huahai Business Overview
7.14.3 Zhejiang Huahai Anti-schizophrenic Drugs Major Product Offerings
7.14.4 Zhejiang Huahai Anti-schizophrenic Drugs Revenue in Global Market (2018-2023)
7.14.5 Zhejiang Huahai Key News & Latest Developments
7.15 Chengdu Kanghong Pharmaceutical
7.15.1 Chengdu Kanghong Pharmaceutical Company Summary
7.15.2 Chengdu Kanghong Pharmaceutical Business Overview
7.15.3 Chengdu Kanghong Pharmaceutical Anti-schizophrenic Drugs Major Product Offerings
7.15.4 Chengdu Kanghong Pharmaceutical Anti-schizophrenic Drugs Revenue in Global Market (2018-2023)
7.15.5 Chengdu Kanghong Pharmaceutical Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(MMG23JU5691 )"抗統合失調症薬のグローバル市場展望 2023年-2029年:錠剤、カプセル、その他" (英文:Anti-schizophrenic Drugs Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。